MX391344B - Compuestos indol sustituidos con dimetoxifenilo como inhibidores de receptores tipo toll 7, 8 o 9 (tlr7, tlr8 o tlr9). - Google Patents
Compuestos indol sustituidos con dimetoxifenilo como inhibidores de receptores tipo toll 7, 8 o 9 (tlr7, tlr8 o tlr9).Info
- Publication number
- MX391344B MX391344B MX2019000694A MX2019000694A MX391344B MX 391344 B MX391344 B MX 391344B MX 2019000694 A MX2019000694 A MX 2019000694A MX 2019000694 A MX2019000694 A MX 2019000694A MX 391344 B MX391344 B MX 391344B
- Authority
- MX
- Mexico
- Prior art keywords
- sub
- toll
- inhibitors
- compounds
- tlr8
- Prior art date
Links
- 102100039390 Toll-like receptor 7 Human genes 0.000 title abstract 2
- 102100033110 Toll-like receptor 8 Human genes 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- -1 DIMETHOXYPHENYL-SUBSTITUTED INDOL COMPOUNDS Chemical class 0.000 title 1
- 101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 title 1
- 101000800483 Homo sapiens Toll-like receptor 8 Proteins 0.000 title 1
- 102000008235 Toll-Like Receptor 9 Human genes 0.000 title 1
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 title 1
- 102000002689 Toll-like receptor Human genes 0.000 title 1
- 108020000411 Toll-like receptor Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 108010060825 Toll-Like Receptor 7 Proteins 0.000 abstract 1
- 108010060752 Toll-Like Receptor 8 Proteins 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000011664 signaling Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201611026137 | 2016-07-30 | ||
| PCT/US2017/044091 WO2018026620A1 (en) | 2016-07-30 | 2017-07-27 | Dimethoxyphenyl substituted indole compounds as tlr7, tlr8 or tlr9 inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2019000694A MX2019000694A (es) | 2019-07-10 |
| MX391344B true MX391344B (es) | 2025-03-21 |
Family
ID=61073069
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019000694A MX391344B (es) | 2016-07-30 | 2017-07-27 | Compuestos indol sustituidos con dimetoxifenilo como inhibidores de receptores tipo toll 7, 8 o 9 (tlr7, tlr8 o tlr9). |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US11180474B2 (enExample) |
| EP (1) | EP3490983B1 (enExample) |
| JP (1) | JP6995109B2 (enExample) |
| KR (1) | KR102506321B1 (enExample) |
| CN (1) | CN109715617B (enExample) |
| AU (1) | AU2017307208B2 (enExample) |
| BR (1) | BR112019001270A2 (enExample) |
| CA (1) | CA3031675A1 (enExample) |
| EA (1) | EA038972B1 (enExample) |
| ES (1) | ES2863474T3 (enExample) |
| IL (1) | IL264462B (enExample) |
| MX (1) | MX391344B (enExample) |
| SG (1) | SG11201900619XA (enExample) |
| WO (1) | WO2018026620A1 (enExample) |
Families Citing this family (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10071079B2 (en) | 2016-06-29 | 2018-09-11 | Bristol-Myers Squibb Company | [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds |
| MX391344B (es) | 2016-07-30 | 2025-03-21 | Bristol Myers Squibb Co | Compuestos indol sustituidos con dimetoxifenilo como inhibidores de receptores tipo toll 7, 8 o 9 (tlr7, tlr8 o tlr9). |
| JP7028861B2 (ja) | 2016-09-09 | 2022-03-02 | ブリストル－マイヤーズ スクイブ カンパニー | ピリジル置換のインドール化合物 |
| FI3526323T3 (fi) | 2016-10-14 | 2023-06-06 | Prec Biosciences Inc | Hepatiitti B -viruksen genomissa oleville tunnistussekvensseille spesifisiä muokattuja meganukleaaseja |
| CN110997656B (zh) | 2017-08-04 | 2023-04-14 | 百时美施贵宝公司 | 用作tlr7/8/9抑制剂的取代的吲哚化合物 |
| ES2921020T3 (es) | 2017-08-04 | 2022-08-16 | Bristol Myers Squibb Co | Compuestos de indol sustituidos con [1,2,4]triazolo[4,3-a]piridinilo |
| WO2019099336A1 (en) | 2017-11-14 | 2019-05-23 | Bristol-Myers Squibb Company | Substituted indole compounds |
| JP2021505555A (ja) * | 2017-12-01 | 2021-02-18 | タイワンジェ ファーマシューティカルズ カンパニー リミテッドＴａｉｗａｎｊ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｃｏ．， Ｌｔｄ． | ベンゼン縮合複素環化合物およびその使用 |
| AU2018386201A1 (en) * | 2017-12-15 | 2020-07-30 | Bristol-Myers Squibb Company | Substituted indole ether compounds |
| JP7289301B2 (ja) | 2017-12-18 | 2023-06-09 | ブリストル－マイヤーズ スクイブ カンパニー | ４－アザインドール化合物 |
| SG11202005704RA (en) | 2017-12-19 | 2020-07-29 | Bristol Myers Squibb Co | 6-azaindole compounds |
| US11878975B2 (en) * | 2017-12-19 | 2024-01-23 | Bristol-Myers Squibb Company | Substituted indole compounds useful as TLR inhibitors |
| CN111511730B (zh) | 2017-12-19 | 2023-07-25 | 百时美施贵宝公司 | 可用作tlr抑制剂的被酰胺取代的吲哚化合物 |
| JP7098748B2 (ja) | 2017-12-20 | 2022-07-11 | インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール，ヴイ．ヴイ．アイ． | Ｓｔｉｎｇアダプタータンパク質を活性化するホスホン酸結合を有する２’３’環状ジヌクレオチド |
| KR102730859B1 (ko) | 2017-12-20 | 2024-11-15 | 브리스톨-마이어스 스큅 컴퍼니 | 아릴 및 헤테로아릴 치환된 인돌 화합물 |
| KR102492187B1 (ko) | 2017-12-20 | 2023-01-27 | 인스티튜트 오브 오가닉 케미스트리 앤드 바이오케미스트리 에이에스 씨알 브이.브이.아이. | Sting 어댑터 단백질을 활성화하는 포스포네이트 결합을 가진 3'3' 사이클릭 다이뉴클레오티드 |
| CA3085937A1 (en) | 2017-12-20 | 2019-06-27 | Bristol-Myers Squibb Company | Diazaindole compounds |
| SG11202005694RA (en) | 2017-12-20 | 2020-07-29 | Bristol Myers Squibb Co | Amino indole compounds useful as tlr inhibitors |
| EP3752505B1 (en) | 2018-02-12 | 2023-01-11 | F. Hoffmann-La Roche AG | Novel sulfone compounds and derivatives for the treatment and prophylaxis of virus infection |
| KR102526964B1 (ko) | 2018-02-26 | 2023-04-28 | 길리애드 사이언시즈, 인코포레이티드 | Hbv 복제 억제제로서의 치환된 피롤리진 화합물 |
| US10870691B2 (en) | 2018-04-05 | 2020-12-22 | Gilead Sciences, Inc. | Antibodies and fragments thereof that bind hepatitis B virus protein X |
| TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | ２，２，─環二核苷酸 |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
| TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
| TW201945388A (zh) | 2018-04-12 | 2019-12-01 | 美商精密生物科學公司 | 對b型肝炎病毒基因體中之識別序列具有特異性之最佳化之經工程化巨核酸酶 |
| US20190359645A1 (en) | 2018-05-03 | 2019-11-28 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotides comprising carbocyclic nucleotide |
| WO2019233941A1 (en) | 2018-06-05 | 2019-12-12 | F. Hoffmann-La Roche Ag | Tetrahydro-1 h-pyrazino[2,1 -ajisoindolylquinoline compounds for the treatment of autoimmune disease |
| US11713327B2 (en) | 2018-06-12 | 2023-08-01 | Hoffmann-La Roche Inc. | Heteroaryl heterocyclyl compounds for the treatment of autoimmune disease |
| JP7366994B2 (ja) | 2018-07-23 | 2023-10-23 | エフ． ホフマン－ラ ロシュ アーゲー | 自己免疫疾患治療用の新規ピペラジン化合物 |
| WO2020028097A1 (en) | 2018-08-01 | 2020-02-06 | Gilead Sciences, Inc. | Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid |
| JP7233809B2 (ja) | 2018-09-04 | 2023-03-07 | エフ． ホフマン－ラ ロシュ アーゲー | 自己免疫疾患の処置のためのベンゾチアゾール化合物 |
| US12252484B2 (en) | 2018-09-06 | 2025-03-18 | Hoffmann-La Roche Inc. | Pyrazolopyridine compounds for the treatment of autoimmune disease |
| WO2020048595A1 (en) | 2018-09-06 | 2020-03-12 | F. Hoffmann-La Roche Ag | Novel cyclic amidine compounds for the treatment of autoimmune disease |
| WO2020086503A1 (en) * | 2018-10-24 | 2020-04-30 | Bristol-Myers Squibb Company | Substituted indole and indazole compounds |
| US11998537B2 (en) | 2018-10-24 | 2024-06-04 | Bristol-Myers Squibb Company | Substituted indole dimer compounds |
| PE20211655A1 (es) | 2018-10-31 | 2021-08-24 | Gilead Sciences Inc | Compuestos de 6-azabencimidazol sustituidos como inhibidores de hpk1 |
| WO2020092528A1 (en) | 2018-10-31 | 2020-05-07 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity |
| US10689360B1 (en) * | 2019-01-30 | 2020-06-23 | Insilico Medicine Ip Limited | TLR inhibitors |
| WO2020178770A1 (en) | 2019-03-07 | 2020-09-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotides and prodrugs thereof |
| WO2020178768A1 (en) | 2019-03-07 | 2020-09-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
| CN113543851B (zh) | 2019-03-07 | 2025-03-18 | 捷克共和国有机化学与生物化学研究所 | 2’3’-环二核苷酸及其前药 |
| TW202212339A (zh) | 2019-04-17 | 2022-04-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TW202210480A (zh) | 2019-04-17 | 2022-03-16 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| KR102904576B1 (ko) * | 2019-05-09 | 2025-12-24 | 브리스톨-마이어스 스큅 컴퍼니 | 치환된 벤즈이미다졸론 화합물 |
| TWI826690B (zh) | 2019-05-23 | 2023-12-21 | 美商基利科學股份有限公司 | 經取代之烯吲哚酮化物及其用途 |
| WO2021034804A1 (en) | 2019-08-19 | 2021-02-25 | Gilead Sciences, Inc. | Pharmaceutical formulations of tenofovir alafenamide |
| EP4458975A3 (en) | 2019-09-30 | 2025-02-12 | Gilead Sciences, Inc. | Hbv vaccines and methods treating hbv |
| WO2021067326A1 (en) | 2019-10-01 | 2021-04-08 | Bristol-Myers Squibb Company | Substituted bicyclic heteroaryl compounds |
| ES2965164T3 (es) | 2019-10-04 | 2024-04-11 | Bristol Myers Squibb Co | Compuestos de carbazol sustituidos |
| EP4051387B1 (en) * | 2019-10-31 | 2025-02-19 | F. Hoffmann-La Roche AG | Hydropyrazino[1,2-d][1,4]diazepine compounds for the treatment of autoimmune disease |
| US12486273B2 (en) | 2019-11-19 | 2025-12-02 | Hoffmann-La Roche Inc. | Hydro-1H-pyrrolo[1,2-a]pyrazine compounds for the treatment of autoimmune disease |
| CN114728988B (zh) | 2019-11-20 | 2024-12-10 | 豪夫迈·罗氏有限公司 | 用于治疗自身免疫性疾病的螺(异苯并呋喃氮杂环丁烷)化合物 |
| ES3022990T3 (en) | 2019-12-06 | 2025-05-29 | Prec Biosciences Inc | Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome |
| CA3169348A1 (en) | 2020-03-20 | 2021-09-23 | Gilead Sciences, Inc. | Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same |
| KR20230053645A (ko) | 2020-08-19 | 2023-04-21 | 브리스톨-마이어스 스큅 컴퍼니 | 섬유증의 치료를 위한 tlr9 억제제로서의 1h-벤조[d]이미다졸 유도체 |
| AU2021328577A1 (en) | 2020-08-19 | 2023-03-23 | Bristol-Myers Squibb Company | 1H-pyrrolo[3,2-c]pyridine and 1H-pyrrolo[2,3-c]pyridine derivatives as TLR9 inhibitors for the treatment of fibrosis |
| US12486267B2 (en) | 2020-08-19 | 2025-12-02 | Bristol-Myers Squibb Company | Imidazo[1,2-A]pyridine and [1,2,4]triazolo[1,5-A]pyridine derivatives as TLR9 inhibitors for the treatment of fibrosis |
| TWI887510B (zh) * | 2020-12-22 | 2025-06-21 | 美商基利科學股份有限公司 | 6-取代之吲哚化合物 |
| TWI838670B (zh) * | 2020-12-22 | 2024-04-11 | 美商基利科學股份有限公司 | 經取代之吲哚化合物 |
| TWI861488B (zh) | 2021-04-16 | 2024-11-11 | 美商基利科學股份有限公司 | 噻吩并吡咯化合物 |
| AU2022274607A1 (en) | 2021-05-13 | 2023-11-16 | Gilead Sciences, Inc. | COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS |
| US11932634B2 (en) | 2021-06-23 | 2024-03-19 | Gilead Sciences, Inc. | Diacylglycerol kinase modulating compounds |
| WO2022271650A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| WO2022271659A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| EP4359415A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| US12070455B2 (en) | 2021-09-10 | 2024-08-27 | Gilead Sciences, Inc. | Thienopyrrole compounds |
| WO2025240243A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with bulevirtide and an inhibitory nucleic acid targeting hepatitis b virus |
| WO2025240242A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
| WO2025240246A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
| WO2025240244A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies comprising bulevirtide and lonafarnib for use in the treatment of hepatitis d virus infection |
| CN118754873B (zh) * | 2024-06-27 | 2025-03-07 | 广东医科大学 | 一种环丁烷吲哚衍生物及其制备方法和应用 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EE200100323A (et) | 1998-12-18 | 2002-08-15 | Axys Pharmaceuticals, Inc. | (Hetero)arüüli - bitsüklilise heteroarüüli derivaadid, nende valmistamine ja nende kasutamine proteaasiinhibiitoritena |
| JP2007524615A (ja) | 2003-06-20 | 2007-08-30 | コーリー ファーマシューティカル ゲーエムベーハー | 低分子トール様レセプター（ｔｌｒ）アンタゴニスト |
| US20060235037A1 (en) * | 2005-04-15 | 2006-10-19 | Purandare Ashok V | Heterocyclic inhibitors of protein arginine methyl transferases |
| JP2009532501A (ja) | 2006-04-04 | 2009-09-10 | ミリアド ジェネティクス， インコーポレイテッド | 疾患および障害のための化合物 |
| DE102006033109A1 (de) | 2006-07-18 | 2008-01-31 | Grünenthal GmbH | Substituierte Heteroaryl-Derivate |
| US8027888B2 (en) | 2006-08-31 | 2011-09-27 | Experian Interactive Innovation Center, Llc | Online credit card prescreen systems and methods |
| ATE495743T1 (de) | 2006-12-01 | 2011-02-15 | Galapagos Nv | Triazolopyridinverbindungen zur behandlung von degenerations- und entzündungskrankheiten |
| WO2008152471A1 (en) | 2007-06-12 | 2008-12-18 | Coley Pharmaceutical Group, Inc. | Quinazoline derivative useful as toll-like receptor antagonist |
| WO2009030996A1 (en) | 2007-09-05 | 2009-03-12 | Coley Pharmaceutical Group, Inc. | Triazole compounds as toll-like receptor (tlr) agonists |
| EP2350032B1 (en) | 2008-09-26 | 2016-05-25 | Eisai R&D Management Co., Ltd. | Benzoxazole compounds and methods of use |
| US8785489B2 (en) | 2008-10-17 | 2014-07-22 | Boehringer Ingelheim International Gmbh | Heteroaryl substituted indole compounds useful as MMP-13 inhibitors |
| TWI462920B (zh) | 2009-06-26 | 2014-12-01 | 葛萊伯格有限公司 | 用於治療退化性及發炎疾病之新穎化合物 |
| TR201809739T4 (tr) | 2009-07-16 | 2018-07-23 | Mallinckrodt Llc | Toll benzeri reseptör 9 antagonistleri olarak (+)-morfinanlar ve bunların terapötik amaçlı kullanımları. |
| US9241991B2 (en) | 2010-10-21 | 2016-01-26 | The Brigham And Women's Hospital, Inc. | Agents, compositions, and methods for treating pruritus and related skin conditions |
| ES2620605T3 (es) | 2011-01-12 | 2017-06-29 | Ventirx Pharmaceuticals, Inc. | Benzoazepinas sustituidas como moduladores de receptores tipo Toll |
| CA2824779C (en) | 2011-01-12 | 2020-01-14 | Array Biopharma, Inc. | Substituted benzoazepines as toll-like receptor modulators |
| WO2012167053A1 (en) | 2011-06-01 | 2012-12-06 | Janus Biotherapeutics, Inc. | Novel immune system modulators |
| RU2606114C2 (ru) | 2011-06-01 | 2017-01-10 | Джейнус Байотерапьютикс, Инк. | Новые модуляторы иммунной системы |
| AU2012267556B9 (en) | 2011-06-09 | 2017-05-11 | Rhizen Pharmaceuticals Sa | Novel compounds as modulators of GPR-119 |
| ES2555167T3 (es) | 2011-07-15 | 2015-12-29 | Janssen Pharmaceuticals, Inc. | Nuevos derivados de indol sustituidos como moduladores de gamma secretasa |
| CA2850932A1 (en) | 2011-10-04 | 2013-04-11 | Janus Biotherapeutics, Inc. | Novel imidazole quinoline-based immune system modulators |
| EP2850067B1 (en) | 2012-05-18 | 2017-08-16 | Sumitomo Dainippon Pharma Co., Ltd. | Carboxylic acid compounds |
| JO3407B1 (ar) | 2012-05-31 | 2019-10-20 | Eisai R&D Man Co Ltd | مركبات رباعي هيدرو بيرازولو بيريميدين |
| EP2738172A1 (en) | 2012-11-28 | 2014-06-04 | Almirall, S.A. | New bicyclic compounds as crac channel modulators |
| US8993771B2 (en) | 2013-03-12 | 2015-03-31 | Novira Therapeutics, Inc. | Hepatitis B antiviral agents |
| TWI624467B (zh) | 2013-10-14 | 2018-05-21 | 衛材Ｒ＆Ｄ企管股份有限公司 | 選擇性經取代之喹啉化合物 |
| CA2933466A1 (en) | 2013-12-13 | 2015-06-18 | Takeda Pharmaceutical Company Limited | Pyrrolo[3,2-c]pyridine derivatives as tlr inhibitors |
| WO2016029077A1 (en) | 2014-08-22 | 2016-02-25 | Janus Biotherapeutics, Inc. | Novel n2, n4, n7, 6-tetrasubstituted pteridine-2,4,7-triamine and 2, 4, 6, 7-tetrasubstituted pteridine compounds and methods of synthesis and use thereof |
| US10071079B2 (en) | 2016-06-29 | 2018-09-11 | Bristol-Myers Squibb Company | [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds |
| MX391344B (es) | 2016-07-30 | 2025-03-21 | Bristol Myers Squibb Co | Compuestos indol sustituidos con dimetoxifenilo como inhibidores de receptores tipo toll 7, 8 o 9 (tlr7, tlr8 o tlr9). |
| JP7028861B2 (ja) | 2016-09-09 | 2022-03-02 | ブリストル－マイヤーズ スクイブ カンパニー | ピリジル置換のインドール化合物 |
-
2017
- 2017-07-27 MX MX2019000694A patent/MX391344B/es unknown
- 2017-07-27 SG SG11201900619XA patent/SG11201900619XA/en unknown
- 2017-07-27 EP EP17764925.8A patent/EP3490983B1/en active Active
- 2017-07-27 WO PCT/US2017/044091 patent/WO2018026620A1/en not_active Ceased
- 2017-07-27 EA EA201990169A patent/EA038972B1/ru unknown
- 2017-07-27 JP JP2019504954A patent/JP6995109B2/ja active Active
- 2017-07-27 CN CN201780058063.4A patent/CN109715617B/zh active Active
- 2017-07-27 AU AU2017307208A patent/AU2017307208B2/en not_active Ceased
- 2017-07-27 BR BR112019001270-2A patent/BR112019001270A2/pt not_active IP Right Cessation
- 2017-07-27 US US16/321,616 patent/US11180474B2/en active Active
- 2017-07-27 CA CA3031675A patent/CA3031675A1/en active Pending
- 2017-07-27 ES ES17764925T patent/ES2863474T3/es active Active
- 2017-07-27 KR KR1020197005484A patent/KR102506321B1/ko active Active
-
2019
- 2019-01-24 IL IL264462A patent/IL264462B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN109715617B (zh) | 2022-04-19 |
| EA201990169A1 (ru) | 2019-07-31 |
| MX2019000694A (es) | 2019-07-10 |
| US11180474B2 (en) | 2021-11-23 |
| EA038972B1 (ru) | 2021-11-16 |
| WO2018026620A1 (en) | 2018-02-08 |
| BR112019001270A2 (pt) | 2019-04-30 |
| KR102506321B1 (ko) | 2023-03-03 |
| US20210292300A1 (en) | 2021-09-23 |
| AU2017307208B2 (en) | 2021-01-21 |
| ES2863474T3 (es) | 2021-10-11 |
| CN109715617A (zh) | 2019-05-03 |
| IL264462B (en) | 2021-12-01 |
| EP3490983A1 (en) | 2019-06-05 |
| KR20190034264A (ko) | 2019-04-01 |
| JP6995109B2 (ja) | 2022-01-14 |
| EP3490983B1 (en) | 2021-02-17 |
| CA3031675A1 (en) | 2018-02-08 |
| JP2019525941A (ja) | 2019-09-12 |
| SG11201900619XA (en) | 2019-02-27 |
| AU2017307208A1 (en) | 2019-03-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201990169A1 (ru) | Диметоксифенилзамещенные соединения индола в качестве ингибиторов tlr7, tlr8 или tlr9 | |
| MX2020005462A (es) | Compuestos de indol sustituidos utiles como inhibidores de receptores tipo toll (tlr). | |
| MX2020005515A (es) | Compuestos de indol sustituidos con amida, utiles como inhibidores de receptores de tipo toll (tlr). | |
| MX2020005513A (es) | Compuestos de amino indol utiles como inhibidores de receptores tipo toll (tlr). | |
| MX2020006168A (es) | Compuestos de 4-azaindol. | |
| MX2020006093A (es) | Compuestos de indol eter sustituidos. | |
| MX2020005622A (es) | Compuestos de indol sustituidos con arilo y heteroarilo. | |
| MX2020005873A (es) | Compuestos de 6-azaindol. | |
| MX2020006014A (es) | Compuestos de diazaindol. | |
| MY196474A (en) | [1,2,4]Triazolo[1,5-A]Pyridinyl Substituted Indole Compounds | |
| MX382383B (es) | Compuestos y composiciones como inhibidores de los receptores endosomales tipo toll | |
| CO2018011064A2 (es) | Inhibidores de bromodominios | |
| CR20200312A (es) | Nuevas piridopirimidinonas sustituidas con bencilamino y derivados como inhibidores de sos1 | |
| EA201790024A1 (ru) | Модуляторы toll-подобных рецепторов для лечения вич | |
| MX2019001096A (es) | Antagonistas del receptor 7/8 tipo toll (tlr7/8) y uso de los mismos. | |
| MX382727B (es) | Derivado de benzazepina, método de preparación, composición farmacéutica y su uso | |
| MY210123A (en) | Tlr7/8 antagonists and uses thereof | |
| MX375323B (es) | Inhibidores de cinasa de interacción con proteína cinasa activada por mitógeno (mnk) y métodos relacionados con los mismos. | |
| BR112013017943A2 (pt) | benzoazepinas substituídas como moduladores receptores do tipo toll | |
| MX2016014308A (es) | Compuestos y composiciones como agonistas del receptor tipo toll 7. | |
| MX373247B (es) | Nuevos derivados de octahidro-pirrolo[3,4-c]-pirrol y análogos del mismo como inhibidores de atotaxina. | |
| EA201791293A1 (ru) | Сайт-специфическое дозирование ингибитора btk | |
| MX376481B (es) | Compuestos de pirazol y su uso como bloqueadores de canales de calcio tipo t. | |
| EA201590228A1 (ru) | Антагонисты 5-ht3 рецептора | |
| MX373162B (es) | Piridopirimidinonas y utilización de las mismas como moduladores de receptores de n-metil-d-aspartato (nmda). |